The all-cash offer values PTC at $205 a share, while Schneider plans new equity and debt financing and targets a Q3 2027 close.

The German IT services company repurchased 2.49 million shares at €3.78 apiece after shareholders tendered nearly twice the number available under the offer.

The PAID 2026-2 securitization drew 27 investors, including four new to Pagaya’s personal-loan ABS platform, as the company broadened its funding base.

CSL will also fund Phase 2 and planned Phase 3 development of lixudebart, while Alentis can earn up to $1.2 billion in commercial milestones and 45% of global profits.

Athabasca holders can elect cash or Cenovus shares, subject to pro-ration, with a shareholder vote expected in late November and closing targeted for December.

AstraZeneca’s $2 billion purchase of Summit convertible preferred stock has closed, giving it rights equivalent to about 12% of outstanding common shares as the companies expand ivonescimab clinical work.

AOI sold 5.69 million shares at an average $105.36 and received about $588 million after fees, with the proceeds aimed largely at expanding data-center optical manufacturing.

The proposed funds target triple the daily moves of reference ETFs spanning artificial intelligence, China technology, gold miners, India, the Magnificent Seven, quantum computing, uranium and global equities.

The company is redeeming its 2028 senior notes in full after refinancing its debt stack with a new $275 million term loan and a $200 million revolving credit facility.

The one-year maturity extensions push Bunge’s $4.2 billion revolving credit agreement to 2031 and its $3.5 billion facility to 2029; a separate $1.1 billion line was extended to 2027.